{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-001465","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.570552+00:00","generated_at":"2026-06-06T05:59:32.723847+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenax Therapeutics enrolls first patient in Phase 3 LEVEL study for TNX-103 in PH-HFpEF; topline data expected H2 2025","bullets":["First patient enrolled in Phase 3 LEVEL study of oral TNX-103 (levosimendan) for PH-HFpEF; 152-patient trial.","Over 40 U.S. and Canadian sites agreed to participate, including Mayo, Harvard, Northwestern.","Topline data forecast for second half of 2025.","FDA does not require long-term CV outcomes trial, reducing cost and time to registration.","Patent estate protects TNX-103 through at least 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-001465","json":"https://secwatch.observer/filing/0001654954-24-001465.json","markdown":"https://secwatch.observer/filing/0001654954-24-001465.md","text":"https://secwatch.observer/filing/0001654954-24-001465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424001465/0001654954-24-001465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424001465/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:59:32.723847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}